Evaluation of fluorescence excitation transfer immunoassay for the measurement of plasma cortisol by Calvin, J. et al.
Journal of Automatic Chemistry of Clinical Laboratory Automation, Vol. 8, No. 2 (April-June 1986), pp. 80-84
Evaluation of fluorescence excitation
transfer immunoassay for the measurement
of plasma cortisol
j. Calvin, K. Burling, R. S. Campbell, S. A. P. Chubb
and C. P. Price
Department of Clinical Biochemistry, Addenbrooke’s Hospital, Cambridge
CB2 2QR, UK
Fluorescence excitation transfer immunoassay is a form
of homogeneous assay suitable for the measurement of
both large and small molecules.
F6rster in 1948 [1] demonstrated that energy can be
transferred through space from a fluorescent donor to an
acceptor molecule; immunoassays based on this observa-
tion have now been developed. In fluorescence excitation
transfer immunoassay, antibody is labelled with acceptor
molecule or ’quencher’, and the antigen with fluorescer
molecules. When the antigen and antibody bind, the
fluorescer and quencher molecules are brought into close
proximity and the fluorescence decreases. Antigen in the
sample competes with the labelled antigen for antibody
sites. Thus a high analyte concentration results in a low
level of quenching and vice versa [2].
The extent of quenching partly depends on the distance
between the quencher and fluorescer [3]; the quenching
rapidly decreasing with increasing distance. For this
reason antibody rather than antigen is labelled with
quencher. If the antibody was labelled with fluorescer,
molecules bound at sites distant from the antigen-
antibody binding site may not be effectively quenched by
labelled antigen. The quencher must absorb at the
wavelength of the fluorescence emission; the higher the
molar absorptivity the greater the quenching efficiency.
For a homogeneous immunoassay the number of
quencher molecules coupled to the antibody is limited by
the effect on the protein solubility and by any background
fluorescence due to the quencher itself [2].
The fluorescence excitation transfer immunoassay for the
measurement ofplasma cortisol uses a fluorescein deriva-
tive (4,5-dimethoxyfluorescein) as the quencher mole-
cule. This compound does not contribute to the back-
ground fluorescence. The hapten, cortisol, is labelled
with 2,7-dimethoxy-4,5-dichlorofluorescein, a dye which
absorbs at 540 nm and emits at 560 nm [4].
This paper reports on the performance ofthe fluorescence
excitation transfer immunoassay technique for the
measurement of plasma cortisol.
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Materials and methods
Instrumentation
The Syva Advance was used to assay samples by
fluorescence excitation transfer immunoassay. The
fluorimeter was calibrated on each working day, accord-
ing to the manufacturer’s recommendations.
Reagents
Cortisol kits were obtained from Syva UK (Syntex
House, Maidenhead, Berkshire, UK).
Plasma pools
Plasma pools containing three levels of analyte were
prepared from patients’ samples. The levels were chosen
for clinical relevance. The pools were aliquoted and
stored at 20 C.
Experimental procedures and results
Imprecision
Samples of each of the plasma pools were analysed on 20
consecutive working days to determine the between-
batch precision. The data are shown in table 1.
A sequence of low (L), medium (M) and high (H) level
samples were run on three separate occasions during the
period of 20 days, permitting the calculation of within-
batch precision on 10 results. The imprecision ranged
from 3"4 to 5"8% (low), 1"8 to 3"2% (medium) and 1"7 to
3"1% (high).
On one occasion two sequences were run on consecutive
carousels to facilitate calculation of the within-batch
imprecision using 20 readings. The data are shown in
table 1.
Table 1. Imprecision.
Cortisol (nmol/1)
Within batch
Mean 267 528 891
S.D. 12.3 20.1 28.5
C.V. (%) 4.6 3.8 3.2
N 20 20 20
Between batch
Mean 204 431 773
S.D. 13.8 22 6 30"2
C.V. (%) 6"8 5’2 3’9
N 20 20 20J. Calvin et al. Evaluation of fluorescence excitation transfer for immunoassay
Carry-over
Using the results obtained from the within-batch impre-
cision studies carry-over was calculated according to the
Dixon formula [5].
The maximum carry-over was 2"6%.
Recovery ofadded analyte
Cortisol (Sigma Chemical Company, Poole, Dorset, UK)
was dissolved in ethanol to give a stock solution of 11
tmol/l. Five patient samples were spiked with the stock
solution (1 in 10 [v/v] and in 20 [v/v]). Results from
specimens with ethanol alone were compared with the
spiked samples. Recovery was found to be in the range 99
to 114%.
Comparison with routine methods
Results from the Advance immunoassay method were
compared with those from a radioimmunoassay method
(Amerlex cortisol kit, Amersham International PLC,
Aylesbury, Buckinghamshire, UK). The Amerlex
method was performed according to the manufacturer’s
instructions. In addition, results were compared with
those from an HPLC technique.
In the HPLC technique the samples were first extracted
using Clin. Elut CE1001 extraction columns (Analyti-
chem International, Inc.). The following were applied, in
order: 100 [1 0" mol/1 hydrochloric acid; 100 1 15 mg/1
hexobarbitone in water; 500 1 cortisol standard (500
nmol/1 in water) or sample; 400 1 water. Two 4 ml
aliquots ofdichloromethane were then allowed to percol-
ate through each column and the effluents collected in
conical glass tubes. The solvent was evaporated at 50C
under a stream of air, and the residues re-dissolved in 100
1 of the mobile phase. 50 tl aliquots were then injected
into the chromatograph.
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Figure 1. Comparison of results for plasma cortisol by Advance
andHPLC methods. Wherey 1"33x 34"58, r 0"944,N
87, SEM 107 nmol/1. [] HPLC calibrator.
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The cortisol was quantitated by the method of peak
height ratios using hexobarbitone as the internal stan-
dard.
Conditions:
Mobile phase
Column
Flow rate
Detection
30% acetonitrile
70% 10 mmol/1 potassium phosphate
pH 3"2
10 [m tBONDAPAK C-18 Radial-
PAK (Waters Associates) and C-18
Guard-PAK
3"0 ml/min
Absorbance at 242 nm; 0"005 AUFS.
A total of 100 samples were analysed by each of the
methods; not all were analysed by all three methods due
to lack of sufficient sample. The data are shown in figures
and 2.
Regression parameters were obtained using the Deming
procedure [6]. Results from calibrator cross-over studies
are also included in the figures.
Figure 2. Comparison of results for plasma cortisol by Advance
andRIA methods. Wherey 0"97x + 10"78, r 0"914,N 95,
SEM 137 nmol/1. /k Advance calibrators and E] RIA
calibrators.
Quality assurance materials
Examples of materials used in a cortisol external quality
assessment scheme were assayed. The data compared
with the Amerlex method consensus mean and also the
GC-MS target value are given in figure 3.
One sample not included in the figure gave a grossly
inaccurate result (Advance result >1518 nmol/1,
Amerlex consensus mean 1155 nmol/1, GCMS target
value 274 nmol/1). This sample was known to contain
prednisolone (2485 nmol/1).
Calibration range and dilution curve
A sample known to contain a level of cortisol in excess of
the quoted range of the Advance system was diluted with
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Figure 3. Comparison of results obtained on samples from the
external quality assurance scheme. Where Advance result,
GC-MS target value, I +2SDs ofthe consensus mean value
for the Amerlex method. The mean values were (i) 359, (ii) 624,
(iii) 928, (iv) 477, (v) 672, (vi) 685, (vii) 588, (viii) 394, (ix)
943, (x) 252, and (xi) 756 nmol/1.
(1) 0"9% saline, and (2) a serum sample with a low
cortisol level, to give a range of dilutions. The assay was
shown to be linear over the range 400 nmol/1 to 1400
nmol/1. Samples diluted to levels below 400 nmol/1 gave
results lower than the expected value.
Stability ofthe calibration curve
The stability of the calibration curve was assessed over a
24 h period. The system was calibrated at 9.00 h and low,
medium and high controls analysed. This routine was
repeated at 11.00, 13.00, 17.00, 21.00, 01.00, 05.00 and
09.00 h. The levels of the controls were then recalculated
against the initial calibration and the results compared
with the levels obtained using the adjacent calibration.
The data are shown in figure 4.
Kit stability
(1) The kit stability over a three-month period was
investigated. A calibration curve, 20 sarnples of a
plasma pool (to assess precision) and a dilution curve
were run using freshly reconstituted reagents. These
reagents were stored at 4C and the protocol
repeated at six and 13 weeks. Results obtained at
week 13 were compared with those obtained with a
new kit. The data are shown in table 2.
(2) The quenching rates for the low and high calibrators
were recorded (in duplicate) and the differences
calculated over a three-month period. The separation
between high and low calibrators did not deviate
outside therange of93"4-113% of the mean value for
the first week.
Investigation of potential interferences
Detection limit
An attempt was made to assess the potential detection
limit ofthe assay by diluting the lowest calibrator 3 in 4,
in 2 and in 4 (v/v). These dilutions were assayed
together with ten replicates of a zero calibrator to
determine the ’base-line noise’. The detection limit was
taken to be the level of analyte giving a signal equivalent
to the mean result for the zero calibrator minus three
times the standard deviation determined within batch.
The detection limit was 27 nmol/1.
Hyperbil rub naemia
The potential interferences due to hyperbilirubinaemia.
was investigated by spiking a plasma pool with solutions
of bilirubin. A stock solution of bilirubin (Sigma Chem-
ical Company, Poole, Dorset, UK) in dimethylsulphox-
ide (6000 mol/l) was prepared. Doubling dilutions ofthe
stock solution were made and added to pooled serum
containing the analyte of interest (1 in 10 [v/v] dilution).
A sample of the pooled plasma with DMSO alone was
also assayed. The data are shown in figure 5.
Table 2. Data to show the performance ofa cortisol kit over a three-month period after reconstition.
Kit after Kit after
Parameter Fresh kit six weeks 12 weeks New kit
Fluorescence rate
Low calibrator
Fluorescence rate
High calibrator
’Separation’
PrecisionN 20
(CV%)
Mean value
tmol/1)
Dilutions ofhigh
concentration
specimen
420"5 393"6 374"2 415’5
419"8 387"0 374"4 414"4
239"3 202"8 184’9 226"3
239"4 201’3 188’8 226"9
181 188 187 188
3’5% 3"3% 1’7% 2"6%
775 844 839 775
Neat >1518 >1518 >1518 >1518
5 + >1518 >1518 >1518 1512
4 + 2 1292 1413 1250 1143
3 + 3 880 1013 972 916
2 + 4 549 629 668 569
+ 5 240 293 309 265
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Figure 4. Assessment ofthefrequency ofcalibration.for the cortisol
assay. Results calculated using the initial calibration (mere) and
the adjacent calibration (wom).
Haemolysis
A sample (10 ml) ofblood was collected from a volunteer,
centrifuged and the red cells washed with isotonic saline.
The red cells were then lysed by resuspension in
deionized water and the solution adjusted with saline to
give a haemoglobin concentration of 5"0 g/dl. This stock
solution was diluted to give a range of haemoglobin
concentrations. A plasma sample was spiked with the
haemoglobin solutions (1 in 10 [v/v]) and cortisol
measured. The data are shown in figure 5.
Table 3. Effect ofseveral compounds on cortisol assay.
800 -.[ . 700
600
500 -
400
Bilirubin 200 400 6oo
Haemoglobin 0.2 0.4 0.6
Triglyceride 2.0 4 0 6.0
(.mol/L)
(g/d1)
8.0 10.0 (mmol/L)
Figure 5. Effect of bilirubin (---), haemoglobin (i)
and lipaemia (w.) on the cortisol assay.
Lipaemia
The turbidity ofpooled plasma was increased by addition
of diluted Intralipid (Kabi Vitrum Ltd, Uxbridge, UK).
The absorbance at 600 nm ofa series ofdiluted specimens
ofknown triglyceride level was used to assess the amount
of Intralipid required. The data are shown in figure 5.
Specific interferences
The following substances were investigated for potential
interference in the cortisol assay; spironolactone, di-
hydroxyandrostenedione sulphate, cyproterone, 17-
hydroxycyproterone, 17-hydroxyprogesterone, dexa-
methasone, 11-deoxycortisol and prednisolone. Each of
the compounds was dissolved in ethanol to give stock
solutions. Each potential interferent was then added
(1 vol) to serum (9 vols); a control was prepared by
substitution of the interferent by ethanol. The cortisol
was then determined in each spiked sample and its
control. The concentrations ofmetabolites were chosen to
reflect the levels observed in pathological conditions. For
the drugs, theoretical peak serum levels were calculated
assuming complete absorption of the compound. Levels
in excess of the theoretical peak level were added to the
assay system. Prednisolone caused gross interference and
was investigated at four concentrations. The data are
shown in table 3.
Compound
Concentration
ofinterferent
in sample
Cortisol measured
(nmol/1)
+ compound compound
Spironolactone
Dihydroxyandrostenedione
sulphate
Cyproterone
17 hydroxymetabolite
ofcyproterone
17 hydroxyprogesterone
Dexamethasone
11-deoxycortisol
Prednisolone
5"8 tmol/1
10 gmol/1
tmol/l
gmol/1
610 617
518 500
517 500
535 500
0"25 mol/1 519 500
510 nmol/1 593 500
570 nmol/1 610 500
1400 nmol/l > 1518 564
700 nmol/1 > 1518 564
350 nmol/1 1087 564
175 nmol/l 789 564
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Conclusion
The cortisol assay was simple to perform and the reagents
were found to be stable for at least three months, after
reconstitution. The precision of the assay compared
favourably with the radioimmunoassay presently in use
in the evaluator’s laboratory. The ’24 h calibration study’
suggested that calibration on every carousel is advisable.
prednisolone. It is debatable whether this is important, in
that it might be claimed that the clinician will always be
aware if a patient is taking prednisolone--however, this
information may not always reach the laboratory and the
appropriate warning may not be given.
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EASTERN ANALYTICAL SYMPOSIUM TO CELEBRATE SILVERJUBILEE
As reflected by a substantial rise in attendance over the last few years, the Eastern Analytical Symposium has
established itself as a significant national and international event in the scientific community.
1986 will mark the 25th annual EAS, which has been christened the Silver Jubilee. To mark this occasion, the
EAS Governing Board has authorized the first-ever five-day EAS. A total of50 technical sessions are planned for
the five days of the meeting, as well as the traditional EAS poster sessions which will be held each day, giving a
substantial increase in the number of papers to be presented at the Silver Jubilee.
In conjunction with the celebration of the Silver Jubilee, the EAS will present the First Eastern Analytical
Symposium Award for Outstanding Contributions to the Fields of Analytical Chemistry.
The SilverJubilee will be the first EAS to take place at the New York Hilton Hotel; the facilities at the Hilton will
permit the expansion of the exposition to accommodate a greater variety of exhibits than has heretofore been
possible, while permitting the exposition to take place in a location exceptionally convenient to all meeting
rooms.
With the move to the Hilton, the EAS has been able to finalize its meeting dates for the next five years
1986: October 6-October 10
1987: September 14-September 18
1988: September 26-September 30
1989: September 24-September 28
1990: September 24-September 28
Details (exhibiting and attending) from Dr S. David Klein, EAS Publicity, 642 Cranbury Cross Road, North Brunswick, New
Jersey.08902, USA. Tel.: 201 846 1582.
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